药物动力学-药物动力学建模框架作为预测耐药性演变的工具
Christopher Witzany1, Jens Rolff2, Roland R Regoes1
1Institute of Integrative Biology, ETH Zurich, Zurich, Switzerland.
这项研究整合了药理动力学-药理动力学 (PKPD) 和人口遗传学模型,以设计最小化抗菌素耐药性演变的药物治疗方法. 新的框架预测在动态选择压力下细菌耐药性的发展.
科学领域:
- 药理学 药理学是指药理学的学科.
- 微生物学 微生物学
- 计算生物学 计算生物学
背景情况:
- 药理动力学-药理动力学 (PKPD) 模型优化药物治疗以消除细菌.
- 抗微生物药物耐药性需要新的策略,重点是防止耐药性演变.
- 现有的模型往往不考虑动态选择压力驱动电阻.
研究的目的:
- 将PKPD与人口遗传学模型结合起来,以预测和最大限度地减少抗菌素耐药性的演变.
- 在动态选择压力下评估耐药性演变,包括改变药物度和适应性表型.
- 为设计治疗方案提供框架,以平衡疗效与避免耐药性.
主要方法:
- 药理动力学-药理动力学 (PKPD) 模型与人口遗传学模型的结合.
- 开发一个建模框架,以评估在动态选择下抵抗演变.
- 分析治疗方案以尽量减少抗药性潜力,以抗生素和抗菌为例.
主要成果:
- 证明PKPD和人口遗传学模型的结合可以识别最小化耐药性演变的治疗方案.
- 该框架允许评估抵抗演变的反应,以动态选择压力.
- 讨论了实证证据和抗生素和抗菌的模型参数.
结论:
- 综合建模为设计防止耐药性演变的抗微生物治疗提供了强大的工具.
- 该框架可以通过各种机制预测细菌的适应和逃离抗微生物药物.
- 进一步扩展可以提高阻力预测模型的现实性和全面性.
更多相关视频
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
14:51Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
Published on: June 17, 2022
相关概念视频
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
Pharmacokinetic Models: Overview
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
Pharmacokinetic Models: Comparison and Selection Criterion
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
Model Approaches for Pharmacokinetic Data: Physiological Models
Analysis of Population Pharmacokinetic Data
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
A recent model describes pravastatin's hepatobiliary excretion,...
